OncoMatch/Brain Cancer — Glioblastoma (GBM)/EGFR
Brain Cancer — Glioblastoma (GBM)EGFR Clinical Trials
EGFR amplification occurs in ~40% of IDH-wild-type GBM, and the EGFRvIII variant (exon 2–7 deletion) is present in ~25%. EGFR-directed therapy in GBM remains an unmet need — small-molecule inhibitors have limited CNS penetration, and the EGFR-directed ADC depatuxizumab mafodotin failed to improve OS in a Phase 3 trial. Trials investigate new-generation EGFR inhibitors, EGFRvIII-targeting CAR-T cells, and bispecific antibody constructs with improved brain penetration.
Top recruiting EGFR Brain Cancer — Glioblastoma (GBM) trials
Ranked by phase and US site count. See all 17 trials matched to your profile →
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Emory University
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Li-kun Chen
Browse other molecular targets with active Brain Cancer — Glioblastoma (GBM) trials.